Compare ARBEW & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBEW | ORMP |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 170.3M |
| IPO Year | 2021 | 2010 |
| Metric | ARBEW | ORMP |
|---|---|---|
| Price | $0.03 | $4.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.9K | ★ 220.5K |
| Earning Date | 03-05-2025 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.69 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.02 | $2.09 |
| 52 Week High | $0.50 | $5.47 |
| Indicator | ARBEW | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 44.66 |
| Support Level | $0.02 | $3.91 |
| Resistance Level | $0.04 | $5.10 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 13.46 | 3.14 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.